Hengdian Group Capital and Apeloa Pharmaceutical to participate in 2025 J.P. Morgan Healthcare Conference

January 10, 2025 01:00 AM AEDT | By Cision
Follow us on Google News: https://kalkinemedia.com/resources/assets/public/images/google-news.webp

HANGZHOU, China, Jan. 9, 2025 /PRNewswire/ -- Hengdian Group Capital (HgC) and Apeloa Pharmaceutical (subsidiaries of Hengdian Group) will attend the 43rd Annual J.P. Morgan Healthcare Conference in San Francisco from January 13-16, 2025.

HgC CEO Gary Xu and Apeloa VP George Cai will be present along with their teams to connect with industry leaders, explore new opportunities and advance their shared mission of driving healthcare innovation.

Please contact HgC at [email protected] or Apeloa at [email protected]m to set up meetings.

About HgC and Apeloa

HgC is the investment and corporate development arm of Hengdian Group, one of the largest family-owned conglomerates in China. With over $350 million USD in assets under management, HgC's sector focus spans Smart Manufacturing & Renewables, Biotech & Medtech, and Film & Consumer. As part of the Group's globalization strategy, HgC seeks to invest, acquire, and/or license-in companies or products that provide synergistic value to the Group or deliver strong growth potential to its portfolio.

HgC's recent notable investments:

  • Zelgen Pharmaceuticals (SHSE: 688266)
  • Weihua New Material (SHSE: 603310)
  • Corxel Pharmaceuticals
  • Atomwise

Apeloa (www.apeloa.com), part of Hengdian Group, is a top five pharmaceutical CDMO in China.  It has been engaged in CDMO for over 20 years with currently eight manufacturing sites and over 2000 employees. Its R&D centers are located in Boston, Shanghai and Hengdian. Its R&D capabilities include flow chemistry, synthetic biology & biocatalysis, highly potent compound, crystallization & particle engineering, TPD/PROTAC, and peptide. Apeloa has the largest manufacturing capacity among the top five CDMOs in China and has been inspected by the US FDA 18 times since 2006.

Apeloa's key milestones in 2024:

  1. Inaugurated new CDMO R&D Center in the US in Greater Boston focusing on preclinical route scouting, scale-up production, and platform development for PROTAC, ADC and peptide synthesis
  2. Celebrated the company's 35th anniversary with a grand gala titled "Together, Towards Tomorrow" at the Palazzo Reale in Milan
  3. Gained FDA approval for Amantadine Hydrochloride tablets, an antidyskinetic medicine used to treat Parkinson's disease and symptoms
  4. Gained FDA approval for Metoprolol Succinate extended-release tablets, used to treat hypertension, angina and chronic heart failure
  5. Launched API product Gabapentin, an epilepsy medication, produced more sustainably and with reduced environmental impact; CEP submitted

Contact:

Mark Xu, [email protected] +86 1575 711 5848 (Media)
Patrick Pan, [email protected] +86 1362 571 2127 (Investors) 


Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media Pty Ltd (“Kalkine Media, we or us”), ACN 629 651 672 and is available for personal and non-commercial use only. The principal purpose of the Content is to educate and inform. The Content does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the Content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stocks of the company(s) or engage in any investment activity under discussion. Kalkine Media is neither licensed nor qualified to provide investment advice through this platform. Users should make their own enquiries about any investments and Kalkine Media strongly suggests the users to seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice), as necessary.
The content published on Kalkine Media also includes feeds sourced from third-party providers. Kalkine does not assert any ownership rights over the content provided by these third-party sources. The inclusion of such feeds on the Website is for informational purposes only. Kalkine does not guarantee the accuracy, completeness, or reliability of the content obtained from third-party feeds. Furthermore, Kalkine Media shall not be held liable for any errors, omissions, or inaccuracies in the content obtained from third-party feeds, nor for any damages or losses arising from the use of such content.
Kalkine Media hereby disclaims any and all the liabilities to any user for any direct, indirect, implied, punitive, special, incidental or other consequential damages arising from any use of the Content on this website, which is provided without warranties. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music that may be used on this website are copyrighted to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures displayed/music used on this website unless stated otherwise. The images/music that may be used on this website are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have made reasonable efforts to accredit the source wherever it was indicated as or found to be necessary.

This disclaimer is subject to change without notice. Users are advised to review this disclaimer periodically for any updates or modifications.

Two ASX Listed Stocks Giving Bullish Indications

Recent Articles

Investing Tips

Previous Next
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.